Method of treating gluten intolerance by means of new S8/S53 endopetidases from the actinomycete Actinoallomurus
US10201593B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Nov 23, 2015 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | Nov 23, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y304/21026
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a new family of proteolytic enxymes having the ability to hydrolize at a pH between 3 and 8 gluten olygopeptides which are resistant to cleavage by gastric and pancreatic enzymes and whose presence in the intestinal lumen results in toxic effects. The enzymes have been identified as endopeptidases of the S8/S53 family and are produced by an Actinoallomurus strain.The object of the invention includes also methods for producing enzymes composition comprising the endopeptidases by cultivation of native Actinoallomurus strains, mutants thereof, or recombinant host cells comprising nucleic acids codifying for the endopeptidases. Said nucleic acids constitute a further object of the invention.The enzyme compositions comprising at least one endopeptidase of the invention are useful for the treatment and/or prevention of celiac sprue, dermatitis herpetiformis and any other disorder associated with gluten intolerance as ingredients of pharmaceutical formulations or as additives of foods and drinks.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.